LEVERKUSEN (dpa-AFX) - Bayer (BAYZF.PK, BAYRY.PK, BYR.L) and Orion Corp.
announced the expansion of the global clinical development program for the
investigational androgen receptor (AR) antagonist BAY-1841788 (ODM-201) in the
area of prostate...
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.